VahatiCor Secures $23M Series B to Advance Cardiac Care Technology

Why It Matters

The funding fast‑tracks development of the only dedicated treatment for CMD, opening a sizable unmet market and offering a therapeutic option for patients who currently have none, while underscoring strong investor confidence in cardiovascular innovation.

Deal Summary

VahatiCor announced the closing of a $23 million Series B round led by S3 Ventures with participation from Intuitive Ventures and a strategic investor. The funding will support enrollment in the SERRA‑I trial, engineering development, and preparation for pivotal studies and regulatory interactions.